KR100864743B1 - 비스포스포네이트의 투여 방법 - Google Patents

비스포스포네이트의 투여 방법 Download PDF

Info

Publication number
KR100864743B1
KR100864743B1 KR1020027017283A KR20027017283A KR100864743B1 KR 100864743 B1 KR100864743 B1 KR 100864743B1 KR 1020027017283 A KR1020027017283 A KR 1020027017283A KR 20027017283 A KR20027017283 A KR 20027017283A KR 100864743 B1 KR100864743 B1 KR 100864743B1
Authority
KR
South Korea
Prior art keywords
treatment
prevention
bisphosphonate
osteoporosis
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027017283A
Other languages
English (en)
Korean (ko)
Other versions
KR20030015283A (ko
Inventor
체불룬 디. 호로비쯔
피터 씨. 리차드슨
울리히 트레치셀
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100864743(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20030015283A publication Critical patent/KR20030015283A/ko
Application granted granted Critical
Publication of KR100864743B1 publication Critical patent/KR100864743B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020027017283A 2000-06-20 2001-06-18 비스포스포네이트의 투여 방법 Expired - Lifetime KR100864743B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US09/597,135 2000-06-20
US26768901P 2001-02-09 2001-02-09
US60/267,689 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (2)

Publication Number Publication Date
KR20030015283A KR20030015283A (ko) 2003-02-20
KR100864743B1 true KR100864743B1 (ko) 2008-10-22

Family

ID=26952565

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017283A Expired - Lifetime KR100864743B1 (ko) 2000-06-20 2001-06-18 비스포스포네이트의 투여 방법

Country Status (24)

Country Link
US (1) US8052987B2 (https=)
EP (1) EP1296689B3 (https=)
JP (2) JP4722375B2 (https=)
KR (1) KR100864743B1 (https=)
CN (1) CN1272013C (https=)
AT (1) ATE304856T1 (https=)
AU (2) AU7410901A (https=)
BR (1) BR0111806A (https=)
CA (1) CA2410201C (https=)
CY (2) CY1113740T1 (https=)
CZ (1) CZ301972B6 (https=)
DE (1) DE60113537T3 (https=)
DK (1) DK1296689T3 (https=)
ES (2) ES2247123T7 (https=)
HU (1) HU228400B1 (https=)
IL (2) IL153229A0 (https=)
MX (1) MXPA02012682A (https=)
NO (1) NO330459B1 (https=)
NZ (1) NZ523086A (https=)
PL (1) PL203087B1 (https=)
PT (1) PT1591122E (https=)
SK (1) SK287278B6 (https=)
TW (1) TWI289451B (https=)
WO (1) WO2001097788A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190685A1 (ko) * 2017-04-14 2018-10-18 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
KR20190007082A (ko) * 2019-01-14 2019-01-21 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
CA2497353C (en) * 2002-09-16 2012-08-28 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
TW200410701A (en) * 2002-10-15 2004-07-01 Novartis Ag Method of administering bisphosphonates
HRP20041013B1 (hr) 2002-12-20 2013-10-25 F. Hoffmann - La Roche Ag Formulacija visoke doze ibandronata
US20070191311A1 (en) * 2004-01-30 2007-08-16 Shuichiro Kakimoto P2x receptor inhibitor
EP1930011B1 (en) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
WO2006062876A2 (en) * 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007124274A1 (en) * 2006-04-21 2007-11-01 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
US20210369769A1 (en) * 2018-11-02 2021-12-02 Dyve Biosciences, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0381296B1 (en) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3776880D1 (de) 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
RU2112515C1 (ru) 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
EP0648120B1 (en) 1992-06-30 1997-12-29 PROCTER & GAMBLE PHARMACEUTICALS, INC. Use of phosphonates for the treatment of osteoporosis
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
EP0779812A4 (en) 1994-09-09 1997-09-10 Procter & Gamble Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
JPH10505091A (ja) 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
ES2239774T3 (es) 1995-09-29 2005-10-01 Novartis Ag Metodo de tratamiento de la enfermedad navicular en caballos.
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
TR200000145T2 (tr) 1997-07-22 2000-05-22 Merck & Co. Inc. Kemik erimesini durdurmak için bir yöntem
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
AU2270101A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190685A1 (ko) * 2017-04-14 2018-10-18 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
US11554129B2 (en) 2017-04-14 2023-01-17 Industry-Academic Cooperation Foundation, Yonsei University Composition for treating chronic renal transplant dysfunction comprising bisphosphonate
KR20190007082A (ko) * 2019-01-14 2019-01-21 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
KR102049233B1 (ko) 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
EP1296689B3 (en) 2013-02-13
PT1591122E (pt) 2012-12-12
CN1272013C (zh) 2006-08-30
JP4722375B2 (ja) 2011-07-13
ATE304856T1 (de) 2005-10-15
DE60113537T3 (de) 2013-05-29
ES2247123T7 (es) 2013-03-01
PL203087B1 (pl) 2009-08-31
CA2410201C (en) 2010-10-26
HUP0301164A3 (en) 2005-11-28
US8052987B2 (en) 2011-11-08
CZ20024134A3 (cs) 2003-06-18
BR0111806A (pt) 2003-05-20
JP2005247873A (ja) 2005-09-15
EP1296689B1 (en) 2005-09-21
AU2001274109B2 (en) 2004-12-23
CY2013011I2 (el) 2015-08-05
JP2003535889A (ja) 2003-12-02
PL358224A1 (en) 2004-08-09
SK18082002A3 (sk) 2003-08-05
AU7410901A (en) 2002-01-02
DK1296689T3 (da) 2005-11-28
SK287278B6 (sk) 2010-05-07
CY1113740T1 (el) 2015-08-05
CY2013011I1 (el) 2015-08-05
EP1296689A2 (en) 2003-04-02
HUP0301164A2 (hu) 2003-08-28
CA2410201A1 (en) 2001-12-27
ES2394211T3 (es) 2013-01-23
DE60113537T2 (de) 2006-06-29
NO330459B1 (no) 2011-04-18
TWI289451B (en) 2007-11-11
NO20026117D0 (no) 2002-12-19
IL153229A0 (en) 2003-07-06
CZ301972B6 (cs) 2010-08-18
NO20026117L (no) 2002-12-19
HU228400B1 (en) 2013-03-28
WO2001097788A2 (en) 2001-12-27
ES2247123T3 (es) 2006-03-01
IL153229A (en) 2007-07-24
CN1620300A (zh) 2005-05-25
WO2001097788A3 (en) 2002-06-27
HK1072539A1 (en) 2005-09-02
NZ523086A (en) 2007-07-27
JP5005188B2 (ja) 2012-08-22
MXPA02012682A (es) 2003-04-25
US20030181421A1 (en) 2003-09-25
KR20030015283A (ko) 2003-02-20
DE60113537D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
KR100864743B1 (ko) 비스포스포네이트의 투여 방법
US20070161603A1 (en) Method of administering bisphosphonates
KR100866025B1 (ko) 통증 치료를 위한 비스포스포네이트의 용도
AU2001274109A1 (en) Method of administering bisphosphonates
RU2297229C2 (ru) Фармацевтическое применение бисфосфонатов
JPH09512816A (ja) プロテーゼのゆるみ及びプロテーゼの移動を防止するための特定メタンビスホスホン酸誘導体の使用
RU2288722C2 (ru) Способ введения бисфосфонатов
HK1072539B (en) Use of bisphosphonates in the preparation of a medicment for the treatment of conditings of abnormally increased bone turnover

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060619

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070509

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071015

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080522

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071015

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070509

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080620

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080522

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080722

Appeal identifier: 2008101005803

Request date: 20080620

AMND Amendment
E701 Decision to grant or registration of patent right
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080630

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080620

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080215

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070709

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060619

Patent event code: PB09011R02I

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20080722

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20081015

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20081015

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110921

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20120924

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130926

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130926

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140923

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150918

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160921

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20211218

Termination category: Expiration of duration